ArticleCellular oncology (Dordrecht, Netherlands)2022

Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8

Biaolong Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.